Prof Garbe talks to ecancertv at EADO 2015 about how and when to combine immunotherapy and targeted therapies to treat melanoma.

Should we use Anti-PD-1 or anti-CTLA-4 in first line therapy?

ecancer's filming at EADO 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

свернуть